Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Colin D. Weekes, Laetitia E. Lamberts, Mitesh J. Borad, Johannes Voortman, Robert R. McWilliams, Jennifer R. Diamond, Elisabeth G. E. de Vries, Henk M. Verheul, Christopher H. Lieu, George P. Kim, Yulei Wang, Suzie J. Scales, Divya Samineni, Flavia Brunstein, YounJeong Choi, Daniel J. Maslyar, Gerardo Colon-Otero

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)439-447
JournalMolecular Cancer Therapeutics
Volume15
Issue number3
DOIs
Publication statusPublished - Mar 2016

Cite this